NCT05969860 |
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer |
NCT05941520 |
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer |
NCT03909282 |
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma |
NCT06188520 |
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors |
NCT05123482 |
A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies |
NCT06471673 |
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer |
NCT06172127 |
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer |
NCT05770531 |
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy |
NCT05464082 |
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC |
NCT05417594 |
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies |
NCT04147494 |
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues |
NCT06780176 |
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida |
NCT05076760 |
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer |
NCT04550494 |
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations |
NCT05020860 |
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer |
NCT05313191 |
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors |
NCT06252662 |
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies |
NCT05766891 |
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery |
NCT05467891 |
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer |
NCT05912231 |
Ultrahypofractionation and Normal Tissue Toxicity |
NCT06428682 |
Role of TXA in Patients Undergoing Breast Free Flap Reconstruction |
NCT05269160 |
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ) |
NCT04824027 |
Breast Elasticity Imaging During Neoadjuvant Chemotherapy |
NCT06545331 |
Study of XB010 in Subjects With Solid Tumors |
NCT05856773 |
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy |
NCT05888831 |
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors |
NCT05092373 |
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax |
NCT03562273 |
GammaPod Registry and Quality of Life Nomogram |
NCT01503190 |
The Immune System's Response to Young Women's Breast Cancer |
NCT06218303 |
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ |
NCT06179303 |
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer |
NCT05422794 |
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer |
NCT04967976 |
Breast Mesh Used in Two-staged Breast Reconstruction |
NCT06686394 |
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) |
NCT06312176 |
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) |
NCT06081127 |
Breast Cancer Pre-habilitation and Prospective Surveillance to Prevent, Detect, and Optimize Physical and Function |
NCT06450873 |
Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery |
NCT05319873 |
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer |
NCT05340673 |
Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer |
NCT02926729 |
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy |
NCT06245889 |
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC |
NCT05544929 |
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers |
NCT05483491 |
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer |
NCT05932862 |
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors |
NCT05208762 |
A Study of SGN-PDL1V in Advanced Solid Tumors |
NCT05579366 |
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) |
NCT06744465 |
NearWave Optical Molecular Monitoring |
NCT05693766 |
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort |
NCT04771520 |
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors |
NCT04756765 |
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer |
NCT06100874 |
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) |
NCT05107674 |
A Study of NX-1607 in Adults With Advanced Malignancies |
NCT05458674 |
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC |
NCT06393374 |
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) |
NCT05933265 |
Study of LP-184 in Patients With Advanced Solid Tumors |
NCT04567420 |
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) |
NCT03572374 |
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job |
NCT06253520 |
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer |
NCT03090165 |
Ribociclib and Bicalutamide in AR+ TNBC |
NCT06904365 |
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women |
NCT05289466 |
Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation. |
NCT04796220 |
Focused Ultrasound and Gemcitabine in Breast Cancer |
NCT05645380 |
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC |
NCT06545682 |
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) |
NCT04998682 |
Prospective Evaluation of Targeted Axillary Dissection (TAD) |
NCT04282044 |
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies |
NCT04703244 |
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer |
NCT04722692 |
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ |
NCT05000294 |
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types |
NCT05238922 |
Study of INCB123667 in Subjects With Advanced Solid Tumors |
NCT05553522 |
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer |
NCT05879926 |
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 |
NCT05056857 |
Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen |
NCT05573126 |
Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer |
NCT06817226 |
BREAST Choice Decision Tool R21 |
NCT06130826 |
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer |
NCT04443348 |
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) |
NCT03351348 |
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control |
NCT05744557 |
Vapocoolant Analgesia for Breast Lymphoscintigraphy |
NCT06533826 |
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd |
NCT06590857 |
Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. |
NCT06275126 |
Optimizing Surgical Decisions in Young Adults With Breast Cancer |
NCT06324357 |
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread |
NCT03524430 |
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy |
NCT05037825 |
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors |
NCT06671730 |
Self-Determination Theory-informed Occupational Therapy Program to Increase Physical Activity Among Survivors of Breast Cancer |
NCT04360330 |
SABER Study for Selected Early Stage Breast Cancer |
NCT04084730 |
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer |
NCT04616248 |
In Situ Immunomodulation with CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients W/ Unresectable and Metastatic Solid Tumors |
NCT05894239 |
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer |
NCT04234386 |
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer |
NCT05020574 |
Microbiome and Association With Implant Infections |
NCT05563220 |
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer |
NCT06297265 |
Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery |
NCT04329065 |
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer |
NCT05183126 |
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer |
NCT05952557 |
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) |
NCT04140526 |
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC |
NCT04768426 |
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer |
NCT06249048 |
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab |
NCT05696626 |
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation |
NCT04959474 |
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer |
NCT05868226 |
PRE-I-SPY Phase I/Ib Oncology Platform Program |
NCT05501886 |
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) |
NCT03546686 |
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women with Triple-negative Breast Cancer |
NCT04841148 |
Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer |
NCT06435429 |
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer |
NCT06673329 |
Brodalumab in the Treatment of Immune-Related Adverse Events |
NCT04648904 |
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer |
NCT06022029 |
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. |
NCT06568692 |
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer |
NCT05736367 |
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer |
NCT04090567 |
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer |
NCT04994067 |
Intra-Operative Radiation Registry |
NCT05464667 |
Preoperative Irradiation for Stage I Breast Cancer |
NCT05417867 |
Evaluating the Association Between Changes in the Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer |
NCT06092892 |
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients with Breast Cancer with Nodal Metastases |
NCT05472792 |
Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN) |
NCT05086692 |
A Beta-only IL-2 ImmunoTherapY Study |
NCT06635980 |
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer |
NCT03930680 |
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane |
NCT04561362 |
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies |
NCT04614194 |
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib |
NCT05150691 |
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors |
NCT05593094 |
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors |
NCT06559540 |
Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer |
NCT03606967 |
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer |
NCT04265872 |
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC |
NCT05972343 |
COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients |
NCT06772181 |
A Digital Health Intervention to Improve Symptoms and Physical Activity During Breast Radiation |
NCT06538389 |
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer |
NCT06157892 |
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors |
NCT06239467 |
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer |
NCT05735080 |
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer |
NCT05720039 |
Robotic vs. Open NSM for Early Stage Breast Cancer |
NCT05768139 |
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors |
NCT05412225 |
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer |
NCT06449222 |
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy |
NCT02896335 |
Palbociclib and Pembrolizumab in Central Nervous System Metastases |
NCT05226663 |
A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer |
NCT04862663 |
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) |
NCT06026657 |
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells with or Without Naxitamab (Danyelza) for the Treatment of Patients with Metastatic, GD2 Expressing, HER2 Negative Breast Cancer |
NCT06518057 |
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer |
NCT06388122 |
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients |
NCT03589339 |
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy |
NCT02743858 |
Lymphedema Surveillance Study |
NCT02476786 |
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score |
NCT06797635 |
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) |
NCT06428396 |
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) |
NCT03990896 |
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial |
NCT05463796 |
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer |
NCT04457596 |
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial |
NCT06584396 |
Evaluating Mechanical Properties of Post-Mastectomy Skin Flaps to Estimate Reconstruction Risks, the EMPOWER Study |
NCT05565534 |
Diabetes Care for Breast Cancer Patients |
NCT02830724 |
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers |
NCT05268224 |
A Tear-based, Lab-developed Test for Breast Cancer for Women With Dense Breast Tissue |
NCT06219434 |
Evaluation of a Mindfulness Intervention to Prevent Chemo-brain in Women Preparing for Chemotherapy for Breast Cancer |
NCT06113016 |
Prevention of Frailty with Fisetin and Exercise (PROFFi) in Breast Cancer Survivors |
NCT04711824 |
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases |
NCT06492616 |
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence |
NCT04022616 |
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients |
NCT04119024 |
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors |
NCT04568616 |
Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) |
NCT05351424 |
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc |
NCT04677816 |
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients |
NCT06315296 |
An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer |
NCT02422641 |
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis |
NCT03096418 |
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response |
NCT05637216 |
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients |
NCT05748834 |
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer |
NCT04371913 |
Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study |
NCT05607017 |
Losartan in Prevention of Radiation-Induced Heart Failure |
NCT06246968 |
A Study of Pembrolizumab and Cryoablation in People with Breast Cancer |
NCT05929768 |
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer |
NCT06408168 |
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial) |
NCT04891068 |
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer |
NCT06027268 |
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer |
NCT06042569 |
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial |
NCT06347068 |
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells |
NCT05892068 |
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain |
NCT05751668 |
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) |
NCT04644068 |
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies |
NCT03270072 |
The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients |
NCT04589468 |
Researching the Effect of Exercise on Cancer |
NCT02772367 |
Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients |
NCT05046301 |
Contrast-Enhanced Mammography for the Evaluation of Mammographic Microcalcifications |
NCT04314401 |
National Cancer Institute "Cancer Moonshot Biobank" |
NCT05795101 |
TRUDI: TDXD+Durva in HER2+/low IBC |
NCT05318469 |
Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer |
NCT06465368 |
A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause |
NCT06099769 |
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer |
NCT06103669 |
Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS) |
NCT06295744 |
Outcomes and Cosmesis With Whole Breast Irradiation and Boost |
NCT06764940 |
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients with Brain Metastases |
NCT05218044 |
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ |
NCT05864144 |
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors |
NCT04475640 |
Cancer Genetic Testing in Ethnic Populations |
NCT05607004 |
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer |
NCT05705401 |
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer |
NCT00899301 |
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer |
NCT05130801 |
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery |
NCT05537740 |
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors |
NCT02701244 |
A Registry Study of Breast Microseed Treatment |
NCT04009044 |
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast |
NCT03671044 |
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients |
NCT03804944 |
Converting HR+ Breast Cancer Into an Individualized Vaccine |
NCT05023967 |
Metformin and Nightly Fasting in Women With Early Breast Cancer |
NCT05837767 |
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue |
NCT05372640 |
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors |
NCT06361940 |
Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients with Hormone Receptor-Positive HER2-negative Breast Cancer |
NCT05059444 |
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation |
NCT05501704 |
ETHAN - ET for Male BC |
NCT06065748 |
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) |
NCT06878248 |
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer |
NCT04039230 |
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. |
NCT04606030 |
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge) |
NCT04485013 |
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers |
NCT05305924 |
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer |
NCT04851613 |
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
NCT03213041 |
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer |
NCT06246786 |
Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) |
NCT02290834 |
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer |
NCT04799535 |
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring |
NCT02735746 |
Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis |
NCT02977468 |
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer |
NCT04606446 |
Study of PF-07248144 in Advanced or Metastatic Solid Tumors |
NCT05245812 |
Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy |
NCT06086704 |
Study of 18F-FFNP Breast PET/MRI |
NCT06671912 |
Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial |
NCT04585750 |
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) |
NCT06400472 |
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors |
NCT04044872 |
Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity |
NCT04906395 |
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer |
NCT06524895 |
Reiki Breast Surgery QOL Project for Women Undergoing Breast Surgery |
NCT06580743 |
Efficacy Verification in Early Diagnosis and Management of Lymphedema Through Home Body Water Analyzer |
NCT06072612 |
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. |
NCT06512350 |
Identifying Patterns in the Breath of Individuals With Breast Cancer |
NCT06461650 |
Preoperative Nicotine Cessation for Women With Breast Cancer Recommended for Reconstruction |
NCT06617455 |
Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial |
NCT05161195 |
Roll-over Study to Allow Continued Access to Ribociclib |
NCT05827614 |
Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications |
NCT05219695 |
Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI) |
NCT03979508 |
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer |
NCT04144023 |
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ |
NCT03987555 |
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients |
NCT04899908 |
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases |
NCT06058650 |
Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities |
NCT05837455 |
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer |
NCT03513614 |
Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS) |
NCT06500455 |
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain |
NCT05323955 |
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib |
NCT06444269 |
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial |
NCT06678269 |
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer |
NCT05703269 |
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy |
NCT05755269 |
Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women |
NCT04389281 |
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma |
NCT04175210 |
Prospective Randomized Study of Accelerated Radiation Therapy (PRART) |
NCT05464810 |
Letrozole with and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer |
NCT05269381 |
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors |
NCT06572410 |
Prospective Analysis of EnVisio Spatial Intelligence for Soft Tissue Localization and Guided Surgical Excision |
NCT05098210 |
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer |
NCT04636710 |
Refining Local-Regional Therapy for IBC |
NCT05230810 |
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. |
NCT05138510 |
Sexual Health in Breast Cancer Patients |
NCT06500481 |
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial |
NCT04886531 |
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers |
NCT06165419 |
Definitive Radiation for High-Risk Spine Metastases |
NCT05785741 |
A Study of DB-1310 in Advanced/Metastatic Solid Tumors |
NCT04222413 |
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors |
NCT06507618 |
Pre-Operative Window of ET to Inform RT Decisions (POWER II) |
NCT04993313 |
Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study |
NCT04787042 |
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 |
NCT04150042 |
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells |
NCT05382299 |
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer |
NCT05561842 |
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries) |
NCT05029999 |
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer |
NCT04115306 |
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer |
NCT05898399 |
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients |
NCT05703399 |
Long Term Followup of Patients Enrolled in MC1137, BEAUTY Study |
NCT04557449 |
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors |
NCT05590949 |
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors |
NCT05035836 |
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) |
NCT06582849 |
Enhanced Assistance During Radiotherapy for Unmet Essential Needs |
NCT06829199 |
A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) |
NCT04674306 |
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer |
NCT06195306 |
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction |
NCT06637306 |
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer |
NCT04333706 |
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) |
NCT06545942 |
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors |
NCT06134375 |
A Study of Tetrathiomolybdate (TM) Plus Capecitabine |
NCT06247995 |
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. |
NCT06220214 |
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer |
NCT05933395 |
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor |
NCT05900895 |
Estradiol Plus Olaparib for Breast Cancer (PHOEBE) |
NCT05708950 |
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) |
NCT04521764 |
A Vaccine (MV-s-NAP) for the Treatment of Patients with Invasive Metastatic Breast Cancer |
NCT05945290 |
Pre-analytical Factors Affecting CtDNA Analysis in Early and Locally Advanced Breast Cancer |
NCT04049214 |
Perioperative Mindfulness Proposal |
NCT05251714 |
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer |
NCT05134779 |
De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You |
NCT06112379 |
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer |
NCT05755984 |
3D Printed Breast Models in the Surgical Management of Breast Cancer |
NCT05870579 |
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer |
NCT05675579 |
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) |
NCT04762979 |
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer |
NCT05507879 |
TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer |
NCT04003038 |
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery |
NCT05505643 |
Cryoablation vs Lumpectomy in T1 Breast Cancers |
NCT05069038 |
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy |
NCT03449238 |
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients |
NCT05592938 |
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) |
NCT05827081 |
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer |
NCT06055881 |
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy |
NCT06184750 |
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial |
NCT06049355 |
EMBRACE: Exercising Together |
NCT06127979 |
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery |
NCT06257264 |
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors |
NCT04965064 |
Trial of Neratinib Plus Capecitabine in Subjects with HER2-Negative Metastatic Breast Cancer with Brain Metastases and Abnormally Active HER2 Signaling |
NCT06103864 |
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer |
NCT05824975 |
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) |
NCT04985032 |
Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT) |
NCT06273852 |
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors |
NCT02250352 |
Core Biopsies for Establishing a Breast Tumor Tissue Repository |
NCT05595499 |
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors |
NCT06270706 |
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors |
NCT06625775 |
Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101) |
NCT06085742 |
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer |
NCT04923542 |
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases |
NCT04169542 |
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients with Breast Cancer Undergoing Breast Surgery |
NCT05053152 |
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study |
NCT04967352 |
Predicting Chronic Pain Following Breast Surgery |
NCT04986579 |
Scalp Cooling in MBC |
NCT05650879 |
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer |
NCT05524584 |
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer |
NCT04683679 |
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer |
NCT05074290 |
Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients |
NCT06409390 |
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer |
NCT06441890 |
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer |
NCT04368702 |
CONFIRM: Magnetic Resonance Guided Radiation Therapy |
NCT01174121 |
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer |
NCT06327490 |
A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer |
NCT05786664 |
Breast Cancer Survivorship Biorepository |
NCT05677802 |
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer |
NCT06833502 |
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer |
NCT06238921 |
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases |
NCT05378464 |
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer |
NCT06144164 |
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer |
NCT04990921 |
Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer |
NCT05949021 |
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer |
NCT03011684 |
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial |
NCT06105684 |
Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer |
NCT02276443 |
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative |
NCT06187103 |
Evaluation of Improved Onboard Patient Imaging |
NCT01042379 |
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer |
NCT05633979 |
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer |
NCT06750484 |
Trial of Trastuzumab Deruxtecan in Previously Treated HER2 |
NCT02945579 |
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy |
NCT04373564 |
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years |
NCT05741164 |
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer |
NCT05826964 |
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer |
NCT04517838 |
Immune Response to Anti-HER2 Therapies in Patients with HER2-Positive Stage I-IV Breast Cancer |
NCT05919108 |
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers |
NCT06328738 |
ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer |
NCT05534438 |
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer |
NCT06018337 |
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) |
NCT04174352 |
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer |
NCT05216432 |
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer |
NCT06351332 |
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in MTNBC |
NCT05315700 |
Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration |
NCT05673200 |
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer |
NCT04802759 |
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer |
NCT04397185 |
Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer |
NCT06582615 |
Food for Thought - a Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer |
NCT04389632 |
A Study of SGN-B6A in Advanced Solid Tumors |
NCT06756932 |
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer |
NCT03808337 |
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease |
NCT04553770 |
Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer |
NCT03796559 |
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes |
NCT06374459 |
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis |
NCT05406232 |
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer |
NCT05768932 |
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia |
NCT05325632 |
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab |
NCT05978232 |
NAVAH Impact on Radiation Therapy Completion in Black Breast & Prostate Cancer Patients |
NCT05608252 |
VS-6766+Abema+Fulv in Met HR+/HER- BC |
NCT06377852 |
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study |
NCT06260332 |
Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors |
NCT05150652 |
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer |
NCT01185132 |
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy |
NCT05374915 |
Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) |
NCT03604315 |
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF |
NCT04895709 |
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors |
NCT03941756 |
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma |
NCT03165487 |
Comparison of the Breast Tumor Microenvironment |
NCT03936478 |
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer |
NCT05376878 |
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis |
NCT05226871 |
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies |
NCT05190978 |
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction |
NCT05291507 |
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System |
NCT05902507 |
Magnetic Resonance Imaging in Radiotherapy for Breast Cancer |
NCT04837209 |
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer |
NCT06139107 |
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole |
NCT05035407 |
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers |
NCT05095207 |
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer |
NCT04650256 |
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences |
NCT05710328 |
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial |
NCT04893109 |
ATEMPT 2.0: Adjuvant T-DM1 Vs TH |
NCT03694756 |
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer |
NCT04300556 |
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types |
NCT03488693 |
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer |
NCT04427293 |
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) |
NCT04603209 |
Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer |
NCT05081609 |
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies |
NCT03971409 |
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer |
NCT04230109 |
Sacituzumab Govitecan In TNBC |
NCT04852887 |
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) |
NCT05989828 |
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer |
NCT05111561 |
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer |
NCT05812807 |
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab |
NCT06439693 |
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer |
NCT06253871 |
A Phase 1/1b Study of IAM1363 in HER2 Cancers |
NCT05891171 |
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers |
NCT04180371 |
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression |
NCT05996107 |
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer |
NCT04563507 |
Combined Immunotherapies in Metastatic ER+ Breast Cancer |
NCT06110793 |
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer |
NCT06763328 |
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy |
NCT03643861 |
RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI) |
NCT06006806 |
Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy |
NCT05508906 |
Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus |
NCT06760637 |
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease |
NCT05064098 |
Interpretations and Predictions of Patient Reported Outcomes by Breast Cancer Patients |
NCT05950945 |
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
NCT03321045 |
Positron Emission Tomography (PET) Imaging with Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness |
NCT06300411 |
SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery |
NCT06460298 |
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer |
NCT05183828 |
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer |
NCT06902311 |
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST) |
NCT04143711 |
Study of DF1001 in Patients with Advanced Solid Tumors |
NCT04454528 |
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy |
NCT05585788 |
Opioid Dispensing Device for Post-Operative Pain in Cancer Patients Patients |
NCT06488378 |
Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer |
NCT06888388 |
Long-term Safety of Nipple Sparing Mastectomy in Women With GPV in Breast Cancer |
NCT05774678 |
Trial of PreoperAtive Radiation (TOPAz): a Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy with Immediate Autologous Breast Reconstruction with Integrated Nanomechanical Biomarker Evaluation |
NCT04704661 |
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial |
NCT00353483 |
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells |
NCT04468061 |
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC |
NCT04815083 |
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery |
NCT05296798 |
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) |
NCT06185205 |
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy |
NCT03934905 |
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction |
NCT03424005 |
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer |
NCT01000883 |
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior |
NCT06120283 |
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors |
NCT05930483 |
Remotely Delivered, Culturally Tailored Weight Loss Interventions Among Latina Breast Cancer Survivors |
NCT02807597 |
Real-time Intraoperative Breast Cancer Visualization for Margin Assessment |
NCT06318897 |
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer |
NCT04075305 |
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study |
NCT06635005 |
A Low-Insulinemic Dietary Intervention to Reduce Breast Cancer Risk in High-Risk Women |
NCT06353997 |
Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients |
NCT01766297 |
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer |
NCT04588545 |
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease |
NCT05557877 |
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer |
NCT06515470 |
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced And/or Metastatic Breast Cancer |
NCT03742245 |
Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer |
NCT03412877 |
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer |
NCT06058377 |
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer |
NCT05564377 |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial |
NCT05288777 |
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer |
NCT06681233 |
Feasibility Study of CBCT for IGRT in Cancer Patients |
NCT05633654 |
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) |
NCT05787587 |
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors |
NCT06129747 |
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast |
NCT05774951 |
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy |
NCT05277051 |
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors |
NCT06380751 |
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer |
NCT05528133 |
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer |
NCT04638751 |
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients |
NCT05867251 |
Study of AVZO-021 in Patients With Advanced Solid Tumors |
NCT03463954 |
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors |
NCT06841354 |
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) |
NCT05514054 |
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
NCT06260033 |
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer |
NCT04315233 |
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics |
NCT05989347 |
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy |
NCT05256745 |
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer |
NCT04494945 |
Identifying and Caring for Individuals With Inherited Cancer Syndrome |
NCT04569747 |
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer |
NCT04348747 |
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer |
NCT05704283 |
3D Ultrasound for the Imaging of Lymph Nodes in Patients with Breast Cancer |
NCT03536897 |
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry |
NCT03789097 |
Vaccination With Flt3L, Radiation, and Poly-ICLC |
NCT06075953 |
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment |
NCT05146297 |
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials |
NCT05746897 |
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors |
NCT05890677 |
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema |